Melatonin for Anxiety

Verdict: Helps only before surgery, not general anxiety

Melatonin has modest, moderate-certainty evidence for easing short-term anxiety right before surgery or procedures, but there is essentially no good evidence it treats generalized or chronic anxiety, and it is not approved for any anxiety use. Because these two situations point in opposite directions, the overall grade is weak and disputed.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is held at Weak/Disputed because the evidence splits sharply by setting. For pre-procedure anxiety, a 2020 Cochrane systematic review (PMID 33319916, n=2319) found melatonin probably lowers preoperative anxiety versus placebo (about 12 points on a 100 mm scale) and works about as well as benzodiazepines like midazolam. This is only moderate certainty, however, since most included trials had unclear or high risk of bias, so it cannot rise to a top grade.

Even within the surgical setting the newer trials disagree. A 2024 sublingual-melatonin trial before cesarean section (PMID 38841008, n=80) showed a clear benefit, but the 2024 MAGIC trial in anxious children (PMID 37953202, n=110) found melatonin clearly inferior to midazolam and was stopped early for futility, and a 2022 trial before hernia repair (PMID 36106858, n=33) found no benefit at all.

Outside surgery the case largely collapses. A 2022 review (PMID 36555831) notes that data for generalized or chronic anxiety remain limited, and regulators offer no support: the FDA finds no basis that melatonin is even safe-by-default (GRAS), EFSA's approved claims cover only sleep onset, and NHS/WHO do not back it for anxiety. Notably, Mayo, Cleveland Clinic, and Harvard list anxiety as a possible side effect of melatonin, not a treatment, which is why the verdict stops short of an endorsement for everyday anxiety.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.62
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
68%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.39
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.616
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Melatonin for preoperative and postoperative anxiety in adults
PMID: 33319916 2020 系統性回顧 n = 2,319
Finding: Melatonin probably reduces preoperative anxiety vs placebo (MD -11.69, 95% CI -13.80 to -9.59; 18 studies, n=1264; moderate-certainty); no meaningful difference vs midazolam/alprazolam (MD 0.78, 95% CI -2.02 to 3.58)
🟢 High quality Academic Effect size: [object Object]
View on PubMed
The MAGIC trial: melatonin versus midazolam in premedication of anxious children for elective surgery
PMID: 37953202 2024 RCT (double-blind) n = 110
Finding: Melatonin inferior to midazolam in anxious children: adjusted mean difference 13.1 (95% CI 3.7-22.4) favoring midazolam; trial stopped early for futility
🟢 High quality Government Effect size: [object Object]
View on PubMed
Sublingual Melatonin Premedication in Young Women Undergoing Cesarean Section With Spinal Anesthesia
PMID: 38841008 2024 RCT (double-blind) n = 80
Finding: Melatonin significantly lower VAS anxiety vs placebo (p<0.001); also reduced HR (p=0.0019) and SBP/DBP (p<0.001)
View on PubMed
Oral melatonin did not reduce anxiety before elective hernia repair: a randomised, double-blinded, placebo-controlled trial
PMID: 36106858 2022 RCT (double-blind) n = 33
Finding: No difference in anxiety: STAI 27 (IQR 24-34) melatonin vs 28 (IQR 24-33) placebo (p=0.814); VAS p=0.813; baseline anxiety low
🟠 Limited quality Effect size: null (NS)
View on PubMed
Melatonin as a Potential Approach to Anxiety Treatment
PMID: 36555831 2022 Other
Finding: Most clinical evidence is perioperative; melatonin equally effective as benzodiazepines without psychomotor impairment; data on GAD/chronic anxiety remain limited; mechanisms include GABAergic, HPA-axis blunting, antioxidant pathways
🟠 Limited quality Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
no basis to conclude that melatonin is GRAS source↗
L4b EU EFSA
Supportive
melatonin and reduction of sleep onset latency source↗
L4c UK NHS
Cautious
Melatonin is available on prescription only. source↗
L4d TW TFDA / 衛福部
Against
褪黑激素產品屬藥品列管 source↗
L4e WHO
Not addressed
altered melatonin excretion source↗
L5a NIH Office of Dietary Supplements
Cautious
short-term use of melatonin supplements appears to be safe source↗
L5b Mayo Clinic
Cautious
Mild anxiety source↗
L5c Cleveland Clinic
Cautious
anxiety, nervousness, confusion source↗
L5d Harvard Health
Against
nausea, dizziness, headaches, and anxiety source↗
L5e Specialty Society (condition-mapped)
Neutral
Efficacy and Safety of Melatonin as an Anxiolytic source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-melatonin-001 繁體中文版 →